VTR Stock Analysis: Ventas | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 41.585m USD | 12M Return: 19.9% | US92276F1003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 325M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 9
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ventas, Inc. (NYSE: VTR) is a Chicago-based S&P 500 healthcare REIT founded in 1983 and publicly listed since 1998. The company owns and operates approximately 1,400 properties across North America and the United Kingdom, anchored by more than 850 senior housing communities and supplemented by outpatient medical buildings, research centers, and other healthcare facilities. Ventas combines an owned-property portfolio with senior housing operating platforms and uses its Ventas OI data platform to guide investment and operational decisions. As a healthcare REIT, Ventas primarily generates revenue through long-term triple-net leases, real estate ownership, and senior housing operations, and is required to distribute the majority of its taxable income to shareholders as dividends.
- Senior housing occupancy and rate growth expand NOI
- Interest rate hikes pressure cap rates and borrowing costs
- Aging population tailwinds drive sustained senior housing demand
| Net Income: 265.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -20.47% < 20% (prev -8.89%; Δ -11.58% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.95b > Net Income 265.6m |
| Net Debt (13.2b) to EBITDA (2.59b): 5.12 < 3 |
| Current Ratio: 0.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (518.9m) vs 12m ago 11.98% < -2% |
| Gross Margin: -0.89% > 18% (prev 41.97%; Δ -42.86% > 0.5%) |
| Asset Turnover: 23.58% > 50% (prev 20.63%; Δ 2.95% > 0%) |
| Interest Coverage Ratio: 1.58 > 6 (EBIT TTM 999.5m / Interest Expense TTM 632.0m) |
| A: -0.05 (Total Current Assets 202.0m - Total Current Liabilities 1.59b) / Total Assets 30.6b |
| B: -0.27 (Retained Earnings -8.14b / Total Assets 30.6b) |
| C: 0.03 (EBIT TTM 999.5m / Avg Total Assets 28.8b) |
| D: 1.11 (Book Value of Equity 15.8b / Total Liabilities 14.3b) |
| Altman-Z'' = 0.23 = B |
| DSRI: 0.48 (Receivables 262.2m/446.1m, Revenue 6.78b/5.56b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.03 (AQ_t 0.98 / AQ_t-1 0.95) |
| SGI: 1.22 (Revenue 6.78b / 5.56b) |
| TATA: -0.05 (NI 265.6m - CFO 1.95b) / TA 30.6b) |
| Beneish M = -3.28 (Cap -4..+1) = AA |
As of November 03, 2026, the stock is trading at USD 86.72 with a total of 5,295,114 shares traded. Over the past week, the price has changed by -0.80%, over one month by +3.23%, over three months by -3.97% and over the past year by +19.87%.
Current recommended Stop Loss: 83.60 (which is 3.6% or 1.3 ATR below the current price).
Ventas has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy VTR.
- StrongBuy: 14
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 99.7 | 15% |
P/E Trailing = 150.1296
P/E Forward = 121.9512
P/S = 6.4784
P/B = 2.7044
P/EG = 4.7503
Revenue TTM = 6.78b USD
EBIT TTM = 999.5m USD
EBITDA TTM = 2.59b USD
Long Term Debt = 12.4b USD (from longTermDebt, last quarter)
Short Term Debt = 17.0m USD (from shortLongTermDebt, last quarter)
Debt = 13.5b USD (from shortLongTermDebtTotal, last fiscal year) + Leases 230.6m
Net Debt = 13.2b USD (calculated: Debt 13.5b - CCE 202.0m)
Enterprise Value = 54.8b USD (41.6b + Debt 13.5b - CCE 202.0m)
Interest Coverage Ratio = 1.58 (Ebit TTM 999.5m / Interest Expense TTM 632.0m)
EV/FCF = 30.32x (Enterprise Value 54.8b / FCF TTM 1.81b)
FCF Yield = 3.30% (FCF TTM 1.81b / Enterprise Value 54.8b)
FCF Margin = 26.66% (FCF TTM 1.81b / Revenue TTM 6.78b)
Net Margin = 3.91% (Net Income TTM 265.6m / Revenue TTM 6.78b)
Gross Margin = -0.89% ((Revenue TTM 6.78b - Cost of Revenue TTM 6.84b) / Revenue TTM)
Gross Margin QoQ = 39.60% (prev 39.82%)
Tobins Q-Ratio = 1.79 (Enterprise Value 54.8b / Total Assets 30.6b)
Interest Expense / Debt = 4.70% (Interest Expense 632.0m / Debt 13.5b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 789.6m (EBIT 999.5m * (1 - 21.00%))
Current Ratio = 0.13 (Total Current Assets 202.0m / Total Current Liabilities 1.59b)
Debt / Equity = 0.85 (Debt 13.5b / totalStockholderEquity, last quarter 15.8b)
Debt / EBITDA = 5.12 (Net Debt 13.2b / EBITDA 2.59b)
Debt / FCF = 7.33 (Net Debt 13.2b / FCF TTM 1.81b)
Total Stockholder Equity = 14.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.92% (Net Income 265.6m / Total Assets 30.6b)
RoE = 1.89% (Net Income TTM 265.6m / Total Stockholder Equity 14.0b)
RoCE = 3.78% (EBIT 999.5m / Capital Employed (Equity 14.0b + L.T.Debt 12.4b))
RoIC = 2.74% (NOPAT 789.6m / Invested Capital 28.8b)
WACC = 4.42% (E(41.6b)/V(55.0b) * Re(4.65%) + D(13.5b)/V(55.0b) * Rd(4.70%) * (1-Tc(0.21)))
Discount Rate = 4.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.10 | Cagr: 10.82%
[DCF] Terminal Value 77.97% ; FCFF base≈1.58b ; Y1≈1.81b ; Y5≈2.67b
[DCF] Fair Price = 52.44 (EV 40.1b - Net Debt 13.2b = Equity 26.9b / Shares 512.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: 98.54 | Revenue CAGR: 16.19% | SUE: 3.16 | # QB: 9
EPS current Quarter (2027-03-31): EPS=0.12 | Chg30d=+4.55% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.61 | Chg30d=+11.65% | Revisions=+0% | GrowthEPS=+12.5% | GrowthRev=+21.8%
EPS next Year (2027-12-31): EPS=0.79 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+79.5% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: -40% (up=0, down=2)